[Column] Government response helped contain Korea’s medical device supply crisis

The recent turmoil in the Middle East disrupted the naphtha supply chain and sent global raw material prices soaring, delivering a direct blow to Korea’s medical device market. Essential consumables, including syringes, suddenly became scarce, sparking fierce competition for inventory among clinics and major hospitals alike.

Even small private clinics that typically purchased supplies online in small quantities were gripped by anxiety. As fears spread, excessive stockpiling intensified, creating a vicious cycle of supply instability. Amid this crisis, the government’s response stood out for its speed and coordination. Authorities moved quickly to calm market distrust and stabilize the situation, offering a valuable model for handling similar emergencies in the future.

Lee Jin-hyu, vice president of the Korea Medical Devices Industry Association

The first reason the government's response deserves praise is its speed. As soon as some media outlets began reporting syringe shortages, the Ministry of Trade, Industry and Energy, Ministry of Health and Welfare and Ministry of Food and Drug Safety immediately launched a joint task force. The government also established a high-level emergency coordination body chaired directly by cabinet ministers, deploying what resembled a military-style operation with systematic, multi-layered strategies.

Authorities launched real-time monitoring across production, distribution and consumption channels while simultaneously developing on-the-spot crisis-response measures. At the peak of market anxiety, these swift actions played a decisive role in calming fears and allowed the government to signal supply stabilization within just a few days.

Second, interagency cooperation was more meticulous and effective than ever before. The task force first conducted a thorough inspection of domestic production and confirmed that syringe supply volumes were actually exceeding normal levels. The problem, it found, was not production capacity but bottlenecks in distribution channels, prompting nationwide investigations in coordination with relevant agencies.

At the same time, the government presented recommended inventory guidelines for major hospitals and wholesalers to discourage excessive competition among purchasers. During the investigation, two key problems emerged: manufacturers notifying supply disruptions due to naphtha shortages, and raw material distributors unfairly raising prices by exploiting fears of scarcity.

The government immediately released stockpiled reserves and promised priority supply to essential medical institutions while also implementing price-stabilization measures. Furthermore, to address regulatory delays caused by changes in raw materials -- a unique challenge in the medical device industry -- the Ministry of Food and Drug Safety introduced fast-track approval measures to support licensing modifications. This coordinated multi-ministerial response generated effects that went beyond the limitations of individual agencies and stabilized the broader supply chain.

The third major strength was the government’s willingness to tackle structural and long-term issues. Amid prolonged currency volatility and global supply instability, the long-standing problem of low reimbursement rates for medical treatment materials came into sharper focus. Rather than merely substituting raw materials, the government confronted the issue directly.

Authorities revised the existing pricing system for medical device treatment materials, which had long relied on a fixed exchange rate. By raising the benchmark exchange rate and widening the allowable fluctuation range, the government enabled pricing structures to better reflect actual market conditions. This was not merely a short-term stabilization measure but a fundamental solution aimed at reducing manufacturers’ financial burdens and strengthening long-term price competitiveness. As a result, market prices remained stable without dramatic spikes, and healthcare providers regained confidence in the supply environment.

Another important aspect of the government’s response was its firm crackdown on market disruptors. Companies attempting to drive up prices through excessive stockpiling were swiftly identified and sanctioned, preventing harm to patients before it could occur. This marked a sharp contrast to past crises involving masks and thermometers, when the burden of risk was effectively shifted onto private businesses, often leaving cooperating companies to absorb heavy losses.

This time, the government released strategic reserves at reasonable prices to minimize market volatility, allowing participating companies to maintain stable operations without major financial damage. The approach demonstrated a more balanced model of public-private cooperation.

Of course, the crisis is not entirely over. Uncertainty surrounding raw material supplies could persist for an extended period, and many challenges remain in preventing future disruptions and ensuring sustainable responses. The most urgent task is securing alternative procurement channels.

Korea’s imported medical device market remains heavily dependent on Western suppliers, with the United States dominating imports, followed by Germany and Japan. Without diversifying this structure, the country will remain vulnerable to geopolitical shocks. For products such as syringes, where technological barriers are relatively low, emerging manufacturing countries including China, India and Vietnam should be actively explored as alternative sources. Government-led policies to diversify import channels, support backup supply chains and strengthen international trade cooperation will be essential.

By building a resilient supply network that can withstand future crises, medical device shortages will no longer pose a threat to public health. The government’s handling of this crisis has set a new standard for emergency management and left behind important lessons for future policymaking.